ClinicalTrials.gg
CompletedNCT05238714Updated Sep 17, 2025

Excretion Balance, Pharmacokinetics, and Metabolism Following of [14C]-Venglustat Administration in Healthy Male Subjects

A Phase 1 interventional study of venglustat in Disorders of Sphingolipid Metabolism and Healthy Volunteers, sponsored by Genzyme, a Sanofi Company. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-17.

Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 1, Interventional, and Screening

From the registry’s dates

  • Primary completion was Jun 2020, 6 years 4 months ago, and no results have been posted to the registry.
  • Registered 1 year 8 months after the study started (first participant enrolled May 2020, registered Feb 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
30 Years to 65 Years
Sex
Male
01

Study summary

Primary Objectives:

  • To determine the excretion balance and systemic exposure of radioactivity after oral administration of [14C]-venglustat.
  • To determine the pharmacokinetics (PK) of venglustat and its contribution to the overall exposure of radioactivity.
  • To determine the metabolic pathways, metabolite profile, chemical structures and main excretion route of the main venglustat metabolites and the metabolite contribution to the overall exposure of radioactivity.

Secondary Objective:

To assess the clinical and biological tolerability of oral solution of venglustat

Read the detailed description

43 days

02

Conditions studied

  • Disorders of Sphingolipid Metabolism
  • Healthy Volunteers
03

In context

Lead sponsor

Genzyme, a Sanofi Company is the lead sponsor of 308 studies on the registry; 5 are open to participants now.

Of its 25 completed or terminated interventional studies of FDA-regulated products, 19 (76%) have results posted.

First submitted after Genzyme became part of Sanofi.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight between 50.0 and 100.0 kg, inclusive, 18 to 32 kg/m2, inclusive
  • Certified as healthy by a comprehensive clinical assessment
  • Normal vital signs after 10 minutes resting in supine position
  • Standard 12-lead (ECG) parameters after 10 minutes resting in supine position in the following ranges; 120 ms≤PR≤230 msec, QRS≤120 msec, ≤450 msec and normal ECG tracing unless the Investigator considers an ECG tracing abnormality to be not
  • Laboratory parameters within the normal range
  • Having given written prior to undertaking any study-related procedure
  • Covered by a health insurance system where applicable, and/or in compliance with the recommendations of the national laws in force relating to biomedical research
  • Not under any administrative or legal supervision
  • Normal renal function as expressed by a >80 mL/min as calculated by the Cockroft and Gault formula
  • Male subjects who agree to use condoms, whose female partner(s) are of (including lactating women), must accept to use, during sexual intercourse, a double method (unless they underwent surgical sterilization) until 90 days after the end of study

Exclusion criteria

Exclusion Criteria:

  • Any history or presence of cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, or infectious disease, or signs of acute illness
  • Frequent headaches and/or migraine, recurrent nausea and/or vomiting (for vomiting only: more than twice a month).
  • Blood donation, any volume, within 3 months before inclusion.
  • Symptomatic postural hypotension, irrespective of the decrease in blood pressure.
  • Presence or history of clinically significant drug , or allergic disease diagnosed and treated by a physician that in the opinion of the Investigator would compromise subject safety.
  • History or presence of drug or alcohol abuse (alcohol consumption more than 14 units per week on a regular basis) in the 5 years prior to screening.
  • Smoking or using nicotine replacement products or e-cigarettes regularly more than 5 cigarettes or equivalent per week, unable to stop smoking during the study (occasional smoker can be enrolled).
  • Excessive consumption of beverages containing xanthine bases (more than 4 cups or glasses per day)
  • Any medication (including St John's Wort) within 14 days before inclusion or within 5 times the elimination half-life or pharmacodynamic half-life of the medication; any vaccination or any medications known to be inducers within the last 28 days and any biologics (antibody or its derivatives) given within 4 months before inclusion
  • Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the Investigator at screening.
  • Any subject who, in the judgment of the Investigator, is likely to be noncompliant during the study, or unable to cooperate because of a language problem or poor mental development.
  • Any subject enrolled in or having participated, in [this or] any other clinical study involving an medicinal product (IMP) according to applicable regulations/guidelines in the 3 months prior to dosing of this study.
  • Any subject who cannot be contacted in case of emergency.
  • Any subject who is the Investigator or any sub investigator, research assistant, pharmacist, study coordinator, or other staff thereof, directly involved in conducting the study
  • Positive result on any of the following tests: surface (HBs Ag) antigen, anti- virus (anti-HCV) antibodies, anti- 1 and 2 antibodies (anti-HIV1 and anti HIV2 Ab).
  • Confirmed positive result on urine drug screen (amphetamines/methamphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, tricyclic antidepressants, opiates including methadone).
  • Positive alcohol breath test
  • Any subject with specific dietary habits, such as vegan.
  • Any subject with irregular bowel habits (more than 3 bowel movements/day or less than 1 every 2 days).
  • Any subject undergoing dental care or presenting with dental caries.
  • Any subject who is occupationally exposed to radiation as defined in the Ionizing Radiations Regulations 2017
  • Participation in a trial with 14C-radiolabelled medication in the 12 months preceding the study.
  • Radiation exposure, including that from the present study and radiopharmaceuticals or radionuclides in therapeutic or diagnostic procedures, but excluding background radiation, exceeding 5 millisievert (mSv) in the last 12 months or 10 mSv in the last 5 years.
  • Any consumption of citrus (grapefruit, orange, etc) or their juices within 5 days before inclusion

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    [14C] venglustat

    Single dose of \[14C\] venglustat Oral Solution under fasting conditions

    Drug: venglustat

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of radioactive dose excreted in urine and faeces

    Percentage of radioactive dose excreted in urine and faeces

    Time frame: Day -1 up to max Day 43

  2. Cmax of plasma and blood radioactivity

    Maximum plasma or blood concentration observed

    Time frame: Day 1 up to max Day 43

  3. AUC Last of plasma and blood radioactivity

    Area under the plasma concentration versus time curve calculated using the trapezoidal method from time zero to the real time, tlast (time corresponding to the last concentration above the limit of quantification, Clast)

    Time frame: Day 1 up to max Day 43

  4. AUC Last of plasma venglustat

    Time frame: Day 1 up to max Day 43

  5. tmax of plasma and blood radioactivity

    Time to Cmax

    Time frame: Day 1 up to max Day 43

  6. tmax of plasma venglustat

    Time to reach Cmax

    Time frame: Day 1 up to max Day 43

Secondary outcomes

  1. Number of participants with adverse events (AEs)

    Number of participants with AEs

    Time frame: Day 1 up to max Day 43

  2. Percentage of venglustat metabolites in plasma

    Percentage of venglustat metabolites in plasma

    Time frame: Day 1 up to max Day 43

  3. Percentage of venglustat metabolites in urine

    Percentage of venglustat metabolites in urine

    Time frame: Day 1 up to max Day 43

  4. Percentage of venglustat metabolites in faeces

    Percentage of venglustat metabolites in faeces

    Time frame: Day 1 up to max Day 43

07

Study locations

1 site
  • Investigational Site Number :8260001
    Nottingham, Nottinghamshire NG11 6JS, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2020 to primary completion in Jun 2020, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2022
First posted
Feb 14, 2022
StartActual
May 26, 2020
Primary completionActual
Jun 26, 2020
CompletionActual
Jun 26, 2020
Last update
Sep 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05238714
Responsible party
Sponsor
First posted
Feb 14, 2022
Start date
May 26, 2020
Primary completion
Jun 26, 2020
Completion
Jun 26, 2020
Last update
Sep 17, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venglustat

Start the discussion